Abstract
Metabasis Therapeutics Inc (previously Ribapharm Inc) is developing pradefovir, an oral liver-targeting prodrug of adefovir developed using its HepDirect technology, for the potential treatment of HBV infection. Phase II clinical trials of pradefovir have been completed.
MeSH terms
-
Adenine / analogs & derivatives*
-
Adenine / chemical synthesis
-
Adenine / pharmacokinetics
-
Adenine / therapeutic use
-
Antiviral Agents* / chemical synthesis
-
Antiviral Agents* / pharmacokinetics
-
Antiviral Agents* / therapeutic use
-
Clinical Trials, Phase I as Topic
-
Clinical Trials, Phase II as Topic
-
Drug Delivery Systems
-
Hepatitis B, Chronic / drug therapy*
-
Humans
-
Liver / metabolism*
-
Organophosphonates* / pharmacokinetics
-
Organophosphonates* / therapeutic use
-
Organophosphorus Compounds* / chemical synthesis
-
Organophosphorus Compounds* / pharmacokinetics
-
Organophosphorus Compounds* / therapeutic use
-
Prodrugs* / chemical synthesis
-
Prodrugs* / pharmacokinetics
-
Prodrugs* / therapeutic use
-
Structure-Activity Relationship
Substances
-
Antiviral Agents
-
Organophosphonates
-
Organophosphorus Compounds
-
Prodrugs
-
adefovir
-
pradefovir
-
Adenine